Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 281.00
Bid: 280.00
Ask: 284.00
Change: -7.00 (-2.43%)
Spread: 4.00 (1.429%)
Open: 282.00
High: 285.00
Low: 281.00
Prev. Close: 288.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS SUMMARY: CVS Group CEO Halves Stake

Fri, 10th Apr 2015 13:02

Director Dealings Summary - Week Ended April 10        
Company Name Position Number of Shares Resulting Holding *Note GBP Value
             
             
BUYS            
             
Hutchison China MediTech  Simon To Chairman 58,000 127,000   800,000
Strategic Minerals John Peters Chairman 1 million 1 million First purchase. 600,000
Hutchison China MediTech  Edith Shih Non-Executive Director 12,000 60,000   166,000
Hydrodec Andrew Black Non-Executive Director 1,750,000 183.6 million Day after Hydrodec agreed to buy Eco-Oil International for GBP2.4 million. 121,000
Dunedin Enterprise Investment Trust Duncan Budge Chairman 20,000 35,900 Week after making GBP5 million investment in Blackrock Programme Management. 68,000
Amerisur Resources John Wardle CEO 248,000 17.6 million Purchased by Tracarta in which Wardle has a beneficial interest. 60,000
Amerisur Resources Douglas Ellenor Non-Executive Director 200,000 1.2 million Same day as pretax profit fell during 2014 and revenue was offset by impairment charge. 50,000
Chime Communications Mervyn Davies Chairman 17,936 67,785   50,000
Synety Graham Ward Non-Executive Director 28,075 234,870 2 days after share placing and open offer. 25,000
JPMorgan Brazil Investment Trust Victor Bulmer-Thomas Non-Executive Director 43,750 159,850   24,000
Hydrodec Colin Moynihan Chairman 310,155 10.2 million Day after Hydrodec agreed to buy Eco-Oil International for GBP2.4 million. 20,000
Xaar Edmund Creutzmann CTO 4,846 4,846 First purchase. 20,000
Dunedin Enterprise Investment Trust Federico Marescott Director 6,000 10,000 Week after making GBP5 million investment in Blackrock Programme Management. 20,000
Synectics Peter Rae Non-Executive Director 14,000 232,302   18,000
Michelmersh Frank Hanna Commercial Director 21,985 1.3 million 2 weeks after reinstating its dividend payout. 15,000
Hydrodec Ian Smale CEO 200,000 1.1 million Day after Hydrodec agreed to buy Eco-Oil International for GBP2.4 million. 14,000
Amerisur Resources Nick Harrison CFO 50,000 5.7 million Same day as pretax profit fell during 2014 and revenue was offset by impairment charge. 12,000
Standard Life Elizabeth Noel Harwerth Non-Executive Director 1,893 10,074   8,900
Concurrent Technologies David Evans-Hughes Engineering Director 8,755 948,206   3,900
             
             
SELLS            
             
Amec Foster Wheeler Kent Masters Non-Executive Director 347,273 70,000 (in the form of ADRs) Week after winning EDF Energy UK nuclear power station deal. 3,800,000
CVS Group Simon Innes CEO 300,000 246,475 Sold more than half his stake. 1,700,000
Domino Printing Sciences  Peter Byrom Chairman 11,932  338,000   111,000
             
             
*Note: A recent company event around the time of the dealing does not suggest the dealing took place because of that event. When a spouse or related party to a director buys shares, the resulting holding is the beneficial holding of the director.
 
             
Contact: +44 207 199 0340; newsroom@alliancenews.com; @AllNewsTeam      
             
Copyright 2015 Alliance News Limited. All Rights Reserved.        

More News
24 Jun 2024 12:20

Hutchmed partner gets European approval for fruqintinib

(Sharecast News) - Hutchmed China announced on Monday that its partner Takeda has received approval from the European Commission for 'Fruzaqla', or fruquintinib, as a monotherapy for adult patients with metastatic colorectal cancer (CRC).

Read more
24 Jun 2024 10:00

IN BRIEF: Hutchmed China notes Takeda obtains EU approval for Fruzaqla

Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Notes that Takeda Pharmaceuticals Co Ltd received a notification from the European Commission that it has approved Fruzaqla, alias fruquintinib, as a monotherapy for adults with metastatic colorectoral cancer who have been previously treated with available standard therapies. Takeda has the exclusive worldwide license to develop, commercialise and manufacture fruquintinib outside of mainland China.

Read more
17 Jun 2024 10:32

Hutchmed celebrates "promising" results for sovleplenib in China

(Alliance News) - Hutchmed (China) Ltd on Monday said its phase 3 trial of sovleplenib showed "consistent benefits" in adults with autoimmune disorder primary immune thrombocytopenia or ITP.

Read more
17 Jun 2024 09:28

Hutchmed publishes positive sovleplenib trial results

(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.

Read more
7 Jun 2024 18:13

IN BRIEF: Hutchmed (China) begins trial of menin inhibitor HMPL-506

Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Says that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignancies in China. The first patient received their first dose on May 31. "This is a Phase I, multicenter, open-label clinical study to evaluate the safety, pharmacokinetics and efficacy of HMPL-506 in patients with hematological malignancies. The study is divided into two phases, a dose escalation phase and a dose expansion phase. The study is expected to enroll at least 60 patients," Hutchmed says. HMPL-506 is a novel, investigational, selective small molecule inhibitor for oral administration targeting the menin protein, it explains.

Read more
17 May 2024 17:58

IN BRIEF: Hutchmed China Simon To leaves role, succeeded by Dan Eldar

Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Chair Simon To retires from his role as chair, succeeded by Dan Eldar, effective immediately. Former chair To agrees to serve as strategic advisor to Hutchmed and will continue to contribute to the company "on significant matters". In a separate release, the company highlights Sovleplenib phase 3 data in adult patients with primary immune thrombocytopenia who have received at least one prior line of standard therapy. ITP is an autoimmune disease characterised by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. Hutchmed will present the data in mid-June in Madrid.

Read more
14 May 2024 14:33

Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies

(Alliance News) - Hutchmed (China) Ltd on Tuesday announced upcoming trials for two of its pipeline cancer treatments, both of which it believes could fill significant clinical gaps.

Read more
14 May 2024 11:42

Hutchmed China launches two cancer treatment trials

(Sharecast News) - Hutchmed China announced the start of two significant clinical trials on Tuesday, aimed at addressing critical unmet needs in cancer treatment.

Read more
3 May 2024 13:37

UK shareholder meetings calendar - next 7 days

Monday 6 May 
no events scheduled 
Tuesday 7 May 
Caledonia Mining Corp PLCAGM
CPPGroup PLCAGM
Just Group PLCAGM
Macfarlane Group PLC AGM
Plus500 LtdAGM
Supernova Digital Assets PLCAGM
Wednesday 8 May 
Airea PLCAGM
Antofagasta PLCAGM
Aston Martin Lagonda Global Holdings PLCAGM
Deltex Medical Group PLCAGM
Direct Line Insurance Group PLCAGM
Fidelity European Trust PLCAGM
Haleon PLCAGM
Jardine Matheson PLCAGM
JZ Capital Partners LtdEGM re investing in a secondary fund
Oscillate PLCAGM
Pershing Square Holdings LtdAGM
Rentokil Initial PLCAGM
WPP PLCAGM
Thursday 9 May 
Ascential PLCAGM
BAE Systems PLCAGM
Balfour Beatty PLCAGM
Barclays PLCAGM
CAB Payments Holdings PLCAGM
Catenai PLCGM re convertible loan note
Clarkson PLCAGM
FBD Holdings PLCAGM
Genel Energy plcAGM
Gym Group PLCAGM
Harbour Energy PLCAGM
Hiscox LtdAGM
IMI PLCAGM
Inchcape PLCAGM
Indivior PLCAGM
John Wood Group PLCAGM
Jupiter Fund Management PLCAGM
Logistics Development Group PLCAGM
Man Group PLCAGM
Morgan Advanced Materials PLCAGM
OSB Group PLCAGM
Public Policy Holding Co IncAGM
Rathbones Group PLCAGM
RM PLCAGM
Spire Healthcare Group PLCAGM
Synthomer PLCAGM
Uniphar PLCAGM
Friday 10 May 
Cairn Homes PLCAGM
Derwent London PLCAGM
Diversified Energy Co PLCAGM
Hutchmed China LtdAGM
Irish Residential Properties REIT PLCAGM
Kenmare Resources PLCAGM
Rightmove PLCAGM
Serinus Energy PLCAGM
Standard Chartered PLCAGM
Wheaton Precious Metals CorpAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
26 Apr 2024 16:09

Hutchmed notes CHMP's positive opinion for fruiquintinib approval

(Alliance News) - Hutchmed (China) Ltd on Friday said that its partner Takeda Pharmaceutical Co Ltd has been notified that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommends approval for fruquintinib.

Read more
5 Apr 2024 11:54

Hutchmed China to make several presentations at cancer research meeting

(Sharecast News) - Hutchmed China announced the upcoming presentation of new and updated data from various studies featuring compounds it had discovered on Friday, at the American Association of Cancer Research (AACR) annual meeting from 5 to 10 April in San Diego, California.

Read more
2 Apr 2024 12:11

Hutchmed endometrial cancer treatment gets priority review in China

(Sharecast News) - Hutchmed China announced the acceptance and granting of priority review by the China National Medical Products Administration (NMPA) for a new drug application combining fruquintinib and sintilimab for the treatment of advanced endometrial cancer on Tuesday.

Read more
2 Apr 2024 10:32

Hutchmed endometrial cancer treatment application accepted for review

(Alliance News) - Hutchmed (China) Ltd on Tuesday jointly announced with Innovent Biologics that their new drug application for the combined fruquintinib and sintilimab treatment for endometrial cancer has been granted priority review by the China National Medical Products Administration.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
28 Mar 2024 13:02

Hutchmed cancer treatment indication accepted for review in China

(Sharecast News) - Hutchmed China announced a significant milestone in its cancer treatment work on Thursday, with the supplemental new drug application (sNDA) for savolitinib had been accepted for review by the China National Medical Products Administration (NMPA).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.